

Supplementary Materials


1. General Experimental Procedures

All experiments dealing with air- and moisture-sensitive compounds were conducted under an atmosphere of dry argon. THF (anhydrous; Wako Pure Chemical Industries, Ltd., Osaka, Japan) was used as received.


For thin-layer chromatography (TLC) analysis, Merck pre-coated plates (silica gel 60 F₂₅₄, Art 5715, 0.25 mm, Merck Japan, Tokyo, Japan) were used. For flash column chromatography, silica gel 60 N (spherical, neutral, 63–210 μm) from Kanto Chemical (Tokyo, Japan) was used.

¹H-NMR and ¹³C-NMR were measured on a JEOL JNM ECA-300 and a JEOL JNM ECX-500II spectrometer (JEOL, Tokyo, Japan). Attenuated Total Reflectance Fourier Transformation Infrared (ATR-FTIR) spectra were recorded on a FT/IR-4200 FT-IR Spectrometer (JASCO, Tokyo, Japan). High resolution mass spectra were obtained with a JEOL JMS 700 spectrometer and a JEOL AccuTOF LC-plus JMS-T100LP. Melting point (mp) determinations were performed by using a MPA100 OptiMelt Automated Melting Point System (OptiMelt, Sunnyvale, California, CA, USA) and are uncorrected.

2. Preparation of 5-Bromo-6-chloro-1,3-diphenylisobenzofuran (9b)




2-Bromo-4,5-dimethylaniline (ii). To a solution of 3,4-dimethylaniline (i) (30.3 g, 250 mmol) in CH₃CN (250 mL) was added *N*-bromosuccinimide (48.9 g, 275 mmol) in CH₃CN (350 mL) through a dropping funnel at 0 °C. After stirring for 0.5 h, the reaction was stopped by adding sat. aq. NaHCO₃. The products were extracted with EtOAc (X3), washed with brine, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was purified by silica-gel flash column chromatography (hexane/EtOAc = 95/5) to give 2-bromo-4,5-dimethylaniline (ii) (41.0 g, 82.0%) as white solids. Recrystallization from hexane gave ii as colorless prisms.




2-Bromo-4,5-dimethylaniline (**ii**). Mp 84.3–85.3 °C (hexane); $^1\text{H-NMR}$ (CDCl_3 , δ) 2.12 (m, 6H), 3.85 (br s, 2H), 6.56 (s, 1H), 7.15 (s, 1H); $^{13}\text{C-NMR}$ (CDCl_3 , δ) 18.5, 19.4, 106.1, 117.2, 128.0, 132.9, 136.8, 141.7; IR (ATR) 3453, 3369, 3020, 2979, 2915, 2878, 1609, 1496, 1450, 1383, 1281, 1150, 970, 874, 853, 731 cm^{-1} ; HRMS (ESI) m/z 200.0082 (200.0075 calcd for $\text{C}_8\text{H}_{11}\text{BrN}$, $[\text{M} + \text{H}]^+$).

1-Bromo-2-chloro-4,5-dimethylbenzene (**iii**). To a suspension of aniline **ii** (20.0 g, 100 mmol) in H_2O (50 mL) was added 12 M HCl (100 mL) and the reaction mixture was cooled to 0 °C, to which was gradually added NaNO_2 (8.99 g, 130 mmol) in H_2O (30 mL) followed by CuCl (12.1 g, 122 mmol) dissolved in 12 M HCl (30 mL) at same temperature. After warmed up to room temperature, the reaction was stirred for further 20 min. The products were extracted with Et_2O (X3), and the combined organic extracts were washed with 25% NH_3 aq. and brine, dried (Na_2SO_4), and concentrated *in vacuo*. Purification of the crude products by recrystallization from MeOH gave 1-bromo-2-chloro-4,5-dimethylbenzene (**iii**) (15.2 g, 69.2%) as colorless prisms.



1-Bromo-2-chloro-4,5-dimethylbenzene (**iii**). Mp 74.1–74.6 °C; $^1\text{H-NMR}$ (CDCl_3 , δ) 2.19 (s, 3H), 2.20 (s, 3H), 7.21 (s, 1H), 7.36 (s, 1H); $^{13}\text{C-NMR}$ (CDCl_3 , δ) 19.0, 19.2, 118.7, 131.0, 134.2, 136.9, 137.4; IR (ATR) 3044, 2978, 2921, 2857, 1590, 1469, 1444, 1382, 1349, 1161, 1123, 1020, 993, 912, 875 cm^{-1} ; HRMS (DART) m/z 217.9508 (217.9498 calcd for $\text{C}_8\text{H}_8\text{BrCl}$, M^+).


4-Bromo-5-chlorophthalic acid (**iv**). A mixture of *o*-xylene **iii** (8.50 g, 38.7 mmol) and KMnO_4 (30.8 g, 195 mmol) in H_2O (300 mL) was refluxed for 20 h. After cooled to room temperature, the reaction was stopped by adding NaHSO_3 followed by aq. KOH. The mixture was filtered through a Büchner funnel and the filtrate was acidified by adding 12 M HCl. The filtration was washed by hexane (X3) to give essentially pure 4-bromo-5-chlorophthalic acid (**iv**) (8.60 g, 79.6%) as white solids. Recrystallization from hexane/acetone gave **iv** as white solids.



4-Bromo-5-chlorophthalic acid (**iv**). Mp decomposed at 300 °C; $^1\text{H-NMR}$ (acetone- d_6 , δ) 7.91 (s, 1H), 8.08 (s, 1H); $^{13}\text{C-NMR}$ (acetone- d_6 , δ) 125.2, 131.2, 133.5, 134.4, 134.9, 137.4, 166.7, 166.9; IR (ATR) 3099, 2812 (br), 1685, 1613, 1526, 1442, 1354, 1271, 1249, 1150, 1091, 919, 896, 759 cm^{-1} ; HRMS (DART) m/z 278.9063 (278.9060 calcd for $\text{C}_8\text{H}_5\text{BrClO}_4$, $[\text{M} + \text{H}]^+$).


Dimethyl 4-bromo-5-chlorophthalate (**v**). To a solution of phthalic acid **iv** (5.60 g, 20.0 mmol) in MeOH (65 mL) was added conc. H_2SO_4 (1.6 mL, 30.0 mmol) at room temperature, and the reaction was refluxed for 5 h. After evaporating the organic solvent, sat. aq. NaHCO_3 was added to the reaction mixture. The products were extracted with EtOAc (X3), and the combined organic extracts were washed with brine, dried (Na_2SO_4), and concentrated *in vacuo*. The residue was purified by silica-gel flash column chromatography

(EtOAc) to give dimethyl 4-bromo-5-chlorophthalate (**v**) (3.76 g, 61.0%). Recrystallization from hexane gave **v** as colorless prisms.



Dimethyl 4-bromo-5-chlorophthalate (v). Mp 45.4–45.9 °C; ¹H-NMR (CDCl₃, δ) 3.91 (m, 6H), 7.80 (s, 1H), 7.99 (s, 1H); ¹³C-NMR (CDCl₃, δ) 53.1, 125.7, 130.6, 131.2, 132.1, 134.2, 137.9, 165.9, 166.1; IR (ATR) 3014, 2961, 2850, 1731, 1588, 1544, 1434, 1356, 1275, 1222, 1121, 1083, 972, 909, 876, 820, 784, 753 cm⁻¹; HRMS (ESI) *m/z* 306.9376 (306.9373 calcd for C₁₀H₉BrClO₄, [M + H]⁺).


Methyl 4-bromo-5-chloro-2-formylbenzoate (vi). To a solution of dimethyl phthalate **v** (3.89 g, 12.6 mmol) in THF (25 mL) was added SDBBA [1] (0.5 M in THF, 39.0 mL, 19.5 mmol) at 0 °C. After 2.5 h, the reaction was stopped by adding 2 M HCl. The products were extracted with EtOAc (X3), and the combined organic extracts were washed with sat. aq. NaHCO₃ and brine, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was purified by silica-gel flash column chromatography (hexane/EtOAc = 9/1) to give methyl 4-bromo-5-chloro-2-formylbenzoate (**vi**) (2.65 g, 75.8%, **vi/vii** = 50/50) as a mixture of regioisomers.



Methyl 4-bromo-5-chloro-2-formylbenzoate (vi) and Methyl 5-bromo-4-chloro-2-formylbenzoate (vii). ¹H-NMR (CDCl₃, δ) 3.99 (s, 6H), 8.00 (s, 1H), 8.08 (s, 1H), 8.20 (s, 1H), 8.28 (s, 1H), 10.59 (s, 1H), 10.60 (s, 1H); ¹³C-NMR (CDCl₃, δ) 53.2, 128.0, 130.0, 130.6, 131.4, 132.3, 133.8, 136.0, 136.8, 139.8, 139.9, 164.7, 164.9, 189.7, 190.0; IR (ATR) 3093, 3023, 2960, 2911, 1712, 1693, 1577, 1547, 1433, 1290, 1273, 1195, 1171, 1095, 960, 916, 903, 837, 780 cm⁻¹; HRMS (DART) *m/z* 276.9267 (276.9267 calcd for C₉H₇BrClO₃, [M + H]⁺).

5-Bromo-6-chloro-1,3-diphenylisobenzofuran (9b). To a solution of methyl 2-formylbenzoate **vi** and **vii** (2.46 g, 8.86 mmol) in THF (15 mL) was added phenylmagnesium bromide (1.0 M in THF, 26.0 mL, 26 mmol) at -40 °C. After warmed up to 0 °C, CF₃CO₂H (5.06 g, 44.4 mmol) was added to the mixture at same temperature, and the reaction stirred for further 10 min. The reaction was stopped by adding sat. aq. NaHCO₃, and the products were extracted with CH₂Cl₂ (X3), washed with brine, dried (Na₂SO₄), and concentrated *in vacuo*. Trituration of the crude products with Et₂O at -78 °C gave 5-bromo-6-chloro-1,3-diphenylisobenzofuran (**9b**) (2.73 g, 80.4%). Recrystallization from hexane/CHCl₃ gave **9b** as yellow needles.

[1] Sodium diisobutyl-*tert*-butoxyaluminium (SDBBA) was prepared as follows: to a solution of sodium *tert*-butoxide (2.44 g, 25.4 mmol) in THF (25 mL) was added diisobutylaluminium hydride (1.0 M in hexane, 25.0 mL, 25.0 mmol) at 0 °C, and the mixture was stirred for 1 h to give SDBBA (0.5 M in THF).



5-Bromo-6-chloro-1,3-diphenylisobenzofuran (9b). Mp 169.3–170.0 °C (hexane/CHCl₃); ¹H-NMR (CDCl₃, δ) 7.30–7.38 (m, 2H), 7.47–7.53 (m, 4H), 7.84–7.89 (m, 4H), 7.96 (s, 1H), 8.18 (s, 1H); ¹³C-NMR (CDCl₃, δ) 119.7, 120.5, 120.7, 121.0, 124.8, 124.88, 124.92, 127.69, 127.74, 129.1, 130.6, 130.8; IR (ATR) 3059, 1599, 1524, 1484, 1443, 1339, 1173, 1065, 967, 900, 856, 797, 753 cm⁻¹; HRMS (DART) *m/z* 382.9831 (382.9838 calcd for C₂₀H₁₃BrClO, [M + H]⁺).

3. ¹H- and ¹³C-NMR Spectra of the Products




Figure S1. ¹H-NMR (300 MHz, CDCl₃) spectrum of aniline **ii**.




Figure S2. ^{13}C -NMR (300 MHz, CDCl_3) spectrum of aniline **ii**.




Figure S3. ^1H -NMR (300 MHz, CDCl_3) spectrum of *o*-xylene **iii**.




Figure S4. ^{13}C -NMR (300 MHz, CDCl_3) spectrum of *o*-xylene **iii**.




Figure S5. ^1H -NMR (300 MHz, $\text{acetone-}d_6$) spectrum of phthalic acid **iv**.




Figure S6. ^{13}C -NMR (300 MHz, acetone- d_6) spectrum of phthalic acid **iv**.




Figure S7. ^1H -NMR (300 MHz, CDCl_3) spectrum of dimethyl phthalate **v**.




Figure S8. ^{13}C -NMR (300 MHz, CDCl_3) spectrum of dimethyl phthalate **v**.




Figure S9. ^1H -NMR (500 MHz, CDCl_3) spectrum of methyl 2-formylbenzoate **vi** and **vii**.




Figure S10. ¹³C-NMR (500 MHz, CDCl₃) spectrum of methyl 2-formylbenzoate **vi** and **vii**.




Figure S11. ¹H-NMR (300 MHz, CDCl₃) spectrum of isobenzofuran **9b**.




Figure S12. ^{13}C -NMR (300 MHz, CDCl_3) spectrum of isobenzofuran **9b**.




Figure S13. ^1H -NMR (300 MHz, CDCl_3) spectrum of cycloadduct **6a**.




Figure S14. $^{13}\text{C-NMR}$ (300 MHz, CDCl_3) spectrum of cycloadduct **6a**.




Figure S15. $^1\text{H-NMR}$ (300 MHz, CDCl_3) spectrum of cycloadduct **7a** (less polar).




Figure S16. ^{13}C -NMR (300 MHz, CDCl_3) spectrum of cycloadduct **7a** (less polar).




Figure S17. ^1H -NMR (300 MHz, CDCl_3) spectrum of cycloadduct **7a** (more polar).




Figure S18. ^{13}C -NMR (300 MHz, CDCl_3) spectrum of cycloadduct **7a** (more polar).




Figure S19. ^1H -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **10**.




Figure S20. ^{13}C -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **10**.




Figure S21. ^1H -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **11** (less polar).




Figure S22. ^{13}C -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **11** (less polar).




Figure S23. ^1H -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **11** (more polar).




Figure S24. ^{13}C -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **11** (more polar).




Figure S25. ^1H -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **12** (a mixture of four diastereomers).




Figure S26. ^{13}C -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **12** (a mixture of four diastereomers).




Figure S27. ^1H -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **13** (less polar).




Figure S28. ^{13}C -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **13** (less polar).




Figure S29. ^1H -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **13** (more polar).




Figure S30. ^{13}C -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **13** (more polar).




Figure S31. ^1H -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **17**.




Figure S32. $^{13}\text{C-NMR}$ (500 MHz, CDCl_3) spectrum of cycloadduct **17**.




Figure S33. $^1\text{H-NMR}$ (500 MHz, CDCl_3) spectrum of cycloadduct **19** (a mixture of two diastereomers).




Figure S34. ¹³C-NMR (500 MHz, CDCl₃) spectrum of cycloadduct **19** (a mixture of two diastereomers).




Figure S35. ¹H-NMR (500 MHz, CDCl₃) spectrum of cycloadduct **21** (less polar).




Figure S36. ¹³C-NMR (500 MHz, CDCl₃) spectrum of cycloadduct **21** (less polar).




Figure S37. ¹H-NMR (500 MHz, CDCl₃) spectrum of cycloadduct **21** (more polar).




Figure S38. ^{13}C -NMR (500 MHz, CDCl_3) spectrum of cycloadduct **21** (more polar).